A preview of the emerging health care companies profiled in the current issue of START-UP: Windhover's Review of Emerging Medical Ventures
Start-Up Previews (4/03)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Orphan Drugs, features profiles of Amicus Therapeutics Inc., Myomatrix Therapeutics LLC and Vipogen LLC. Plus these Start-Ups across Health Care: Advagen Inc., Aviva Biosciences Corp., Gene Network Sciences Inc., Hypnion Inc. and Savacor Inc.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
Sponsored by:
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
• By
Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.
• By
A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.
• By
Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.